Clinical Trial Update: OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas [Phase 1]

View source ↗

Summary

A Phase 1 pilot trial of OXC401 (fosbretabulin) with bevacizumab for recurrent high-grade gliomas has been withdrawn. The study involves central nervous system …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumor
• High-grade Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• OXC401 (fosbretabulin tromethamine)

Snippet

Sponsor: West Virginia University | Conditions: Central Nervous System Tumors | Phase 1 | Status: WITHDRAWN